1. Breast Cancer Res. 2018 Apr 17;20(1):28. doi: 10.1186/s13058-018-0951-9.

Morphology and genomic hallmarks of breast tumours developed by ATM deleterious 
variant carriers.

Renault AL(1)(2)(3)(4), Mebirouk N(1)(2)(3)(4), Fuhrmann L(5), Bataillon G(5), 
Cavaciuti E(1)(2)(3)(4), Le Gal D(1)(2)(3)(4), Girard E(1)(2)(3)(4), Popova 
T(2)(3)(6), La Rosa P(1)(2)(3)(4), Beauvallet J(1)(2)(3)(4), Eon-Marchais 
S(1)(2)(3)(4), Dondon MG(1)(2)(3)(4), d'Enghien CD(7), Laugé A(7), Chemlali 
W(8), Raynal V(9), Labbé M(1)(2)(3)(4), Bièche I(8), Baulande S(9), Bay JO(10), 
Berthet P(11), Caron O(12), Buecher B(7), Faivre L(13)(14), Fresnay M(15), 
Gauthier-Villars M(7), Gesta P(16), Janin N(17), Lejeune S(18), Maugard 
C(19)(20), Moutton S(21), Venat-Bouvet L(22), Zattara H(23), Fricker JP(24), 
Gladieff L(25), Coupier I(26)(27); CoF-AT; GENESIS; kConFab; Chenevix-Trench 
G(28), Hall J(29)(30)(31), Vincent-Salomon A(5), Stoppa-Lyonnet D(6)(7)(32), 
Andrieu N(1)(2)(3)(4), Lesueur F(33)(34)(35)(36).

Author information:
(1)INSERM, U900, Paris, France.
(2)Institut Curie, Paris, France.
(3)Mines Paris Tech, Fontainebleau, France.
(4)PSL Research University, Paris, France.
(5)Service de Pathologie, Institut Curie, Paris, France.
(6)INSERM U830, Paris, France.
(7)Service de Génétique, Institut Curie, Paris, France.
(8)Unité de Pharmacogénomique, Institut Curie, Paris, France.
(9)Institut Curie Genomics of Excellence (ICGex) Platform, Institut Curie, 
Paris, France.
(10)CHU Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France.
(11)Unité de Pathologie Gynécologique, Centre François Baclesse, Caen, France.
(12)Service d'Oncologie Génétique, Gustave Roussy, Villejuif, France.
(13)Institut GIMI, CHU de Dijon, Hôpital d'Enfants, Dijon, France.
(14)Oncogénétique, Centre de Lutte contre le Cancer Georges François Leclerc, 
Dijon, France.
(15)Département d'Hématologie et d'Oncologie Médicale, CLCC Antoine Lacassagne, 
Nice, France.
(16)Service d'Oncogénétique Régional Poitou-Charentes, Centre Hospitalier 
Georges-Renon, Niort, France.
(17)Service de Génétique, Clinique Universitaire Saint-Luc, Brussels, Belgium.
(18)Service de Génétique Clinique Guy Fontaine, Hôpital Jeanne de Flandre, 
Lille, France.
(19)Laboratoire de Diagnostic Génétique, UF1422 Oncogénétique Moléculaire, 
Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
(20)Oncogénétique Evaluation familiale et suivi, UF6948 Oncogénétique, Hôpitaux 
Universitaires de Strasbourg, Strasbourg, France.
(21)Laboratoire Maladies Rares: Génétique et Métabolisme, CHU de Bordeaux-GH 
Pellegrin, Bordeaux, France.
(22)Service d'Oncologie Médicale, Hôpital Universitaire Dupuytren, Limoges, 
France.
(23)Département de Génétique, Hôpital de la Timone, Marseille, France.
(24)Unité d'Oncogénétique, Centre Paul Strauss, Strasbourg, France.
(25)IUCT Oncopole, Institut Claudius Regaud, Toulouse, France.
(26)Service de Génétique Médicale et Oncogénétique, Hôpital Arnaud de 
Villeneuve, CHU de Montpellier, Montpellier, France.
(27)Unité d'Oncogénétique, ICM Val d'Aurelle, Montpellier, France.
(28)Department of Genetics and Computational Biology, QIMR Berghofer Medical 
Research Institute, Brisbane, Australia.
(29)UMR INSERM 1052, Lyon, France.
(30)CNRS 5286, Lyon, France.
(31)Centre de Recherche en Cancérologie de Lyon, Lyon, France.
(32)Université Paris Descartes, Paris, France.
(33)INSERM, U900, Paris, France. fabienne.lesueur@curie.fr.
(34)Institut Curie, Paris, France. fabienne.lesueur@curie.fr.
(35)Mines Paris Tech, Fontainebleau, France. fabienne.lesueur@curie.fr.
(36)PSL Research University, Paris, France. fabienne.lesueur@curie.fr.

BACKGROUND: The ataxia telangiectasia mutated (ATM) gene is a moderate-risk 
breast cancer susceptibility gene; germline loss-of-function variants are found 
in up to 3% of hereditary breast and ovarian cancer (HBOC) families who undergo 
genetic testing. So far, no clear histopathological and molecular features of 
breast tumours occurring in ATM deleterious variant carriers have been 
described, but identification of an ATM-associated tumour signature may help in 
patient management.
METHODS: To characterise hallmarks of ATM-associated tumours, we performed 
systematic pathology review of tumours from 21 participants from 
ataxia-telangiectasia families and 18 participants from HBOC families, as well 
as copy number profiling on a subset of 23 tumours. Morphology of ATM-associated 
tumours was compared with that of 599 patients with no BRCA1 and BRCA2 mutations 
from a hospital-based series, as well as with data from The Cancer Genome Atlas. 
Absolute copy number and loss of heterozygosity (LOH) profiles were obtained 
from the OncoScan SNP array. In addition, we performed whole-genome sequencing 
on four tumours from ATM loss-of-function variant carriers with available frozen 
material.
RESULTS: We found that ATM-associated tumours belong mostly to the luminal B 
subtype, are tetraploid and show LOH at the ATM locus at 11q22-23. Unlike 
tumours in which BRCA1 or BRCA2 is inactivated, tumours arising in ATM 
deleterious variant carriers are not associated with increased large-scale 
genomic instability as measured by the large-scale state transitions signature. 
Losses at 13q14.11-q14.3, 17p13.2-p12, 21p11.2-p11.1 and 22q11.23 were observed. 
Somatic alterations at these loci may therefore represent biomarkers for ATM 
testing and harbour driver mutations in potentially 'druggable' genes that would 
allow patients to be directed towards tailored therapeutic strategies.
CONCLUSIONS: Although ATM is involved in the DNA damage response, ATM-associated 
tumours are distinct from BRCA1-associated tumours in terms of morphological 
characteristics and genomic alterations, and they are also distinguishable from 
sporadic breast tumours, thus opening up the possibility to identify ATM variant 
carriers outside the ataxia-telangiectasia disorder and direct them towards 
effective cancer risk management and therapeutic strategies.

DOI: 10.1186/s13058-018-0951-9
PMCID: PMC5905168
PMID: 29665859 [Indexed for MEDLINE]

Conflict of interest statement: ETHICS APPROVAL AND CONSENT TO PARTICIPATE: 
Written informed consent for genetic studies and use of medical records for the 
present analyses was obtained from all participants enrolled in the Retro-AT, 
CoF-AT, GENESIS and kConFab research programs. The appropriate local ethics 
committee (Comité de Protection des Personnes [CCP] Ile-de-France III 2002/2006) 
and the French data protection authority (Commission Nationale de l’Informatique 
et des Libertés [CNIL]) approved the individual resource collections; Retro-AT, 
CoF-AT, and GENESIS study protocols; and the specific study on tumour material 
of ATM carriers. The kConFab resource collection and the specific study on 
tumour material of ATM carriers were approved by the Peter MacCallum Cancer 
Centre Ethics Committee and the Queensland Institute of Medical Research Human 
Research Ethics Committee. CONSENT FOR PUBLICATION: Not applicable. COMPETING 
INTERESTS: The authors declare that they have no competing interests. 
PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional 
claims in published maps and institutional affiliations.